PMV Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q2 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
PMV Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q2 2021 to Q3 2024.
  • PMV Pharmaceuticals, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 11.7 %, a 13.6% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 11.7 +1.4 +13.6% Sep 30, 2024
Q2 2024 10.9 +0.85 +8.43% Jun 30, 2024
Q1 2024 11 +1.61 +17.1% Mar 31, 2024
Q4 2023 10.8 +1.95 +22.1% Dec 31, 2023
Q3 2023 10.3 +2.08 +25.3% Sep 30, 2023
Q2 2023 10.1 +2.68 +36.2% Jun 30, 2023
Q1 2023 9.41 +2.8 +42.4% Mar 31, 2023
Q4 2022 8.81 +3.78 +75.1% Dec 31, 2022
Q3 2022 8.22 +4.58 +126% Sep 30, 2022
Q2 2022 7.4 +4.85 +190% Jun 30, 2022
Q1 2022 6.61 Mar 31, 2022
Q4 2021 5.03 Dec 31, 2021
Q3 2021 3.63 Sep 30, 2021
Q2 2021 2.55 Jun 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.